At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 325 enrolled
Drug / intervention
SDN-037 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Masked, Parallel Group, Multicenter, Study To Evaluate Efficacy And Safety of SDN -037 Twice Daily Compared With Vehicle For The Treatment Of Inflammation And Pain Associated With Ocular Surgery.
In Brief
A Phase 3 clinical trial evaluating SDN-037 and Placebo for Inflammation and Pain Associated With Ocular Surgery. Completed, enrolled 325 participants across 19 sites.
Detailed Summary
The efficacy and safety of SDN-037 twice daily will be evaluated and compared with vehicle for the treatment of inflammation and pain associated with ocular surgery.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
201820192020202120222023202420252026
First PostedFeb 2018
Enrollment StartSep 2018
Primary CompletionMar 2020
TodayJul 2026
First PostedFeb 8, 2018
Enrollment StartSep 28, 2018
Primary CompletionMar 5, 2020
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 8.4 years ago
Interventions
SDN-037drug
twice daily
Placebodrug
twice daily